[Oncoimmunology in old age].
Onkoimmunologie im Alter.
Carcinogenesis
Checkpoint inhibitors
Head and neck neoplasms
Immunosenescence
Immunotherapy
Journal
HNO
ISSN: 1433-0458
Titre abrégé: HNO
Pays: Germany
ID NLM: 2985099R
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
29
9
2019
medline:
3
3
2020
entrez:
28
9
2019
Statut:
ppublish
Résumé
Physiological aging processes of the immune system are associated with an increased susceptibility to infectious, autoimmune and tumor diseases. In accordance with the general demographic development the number of tumor patients in advanced age also increases. An end to this development is not yet foreseeable. In tumor treatment, immunotherapy with checkpoint inhibitors is becoming increasingly more important; however, only a few studies on the efficacy and side-effect profiles in older patients exist so far. In this review article the changes in the immune system in old age and the influence on carcinogenesis are discussed. In addition, the current state of research on the immunotherapy of patients in advanced age who suffer from head and neck cancer is presented.
Identifiants
pubmed: 31559466
doi: 10.1007/s00106-019-00758-3
pii: 10.1007/s00106-019-00758-3
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
177-183Références
Semin Immunol. 2012 Oct;24(5):342-9
pubmed: 22560930
J Immunol. 2006 Dec 15;177(12):8348-55
pubmed: 17142731
PLoS One. 2014 Mar 17;9(3):e91551
pubmed: 24637664
J Immunol. 2002 Jun 1;168(11):5893-9
pubmed: 12023394
Nature. 2007 Jun 7;447(7145):725-9
pubmed: 17554309
Nat Rev Immunol. 2013 Dec;13(12):875-87
pubmed: 24157572
Front Microbiol. 2016 Dec 27;7:2111
pubmed: 28082969
Immun Ageing. 2013 Sep 06;10(1):38
pubmed: 24010581
Blood. 2000 May 1;95(9):2860-8
pubmed: 10779432
Front Immunol. 2016 Feb 25;7:41
pubmed: 26941738
J Leukoc Biol. 2015 Dec;98(6):937-43
pubmed: 26188078
Blood. 2005 Mar 15;105(6):2294-9
pubmed: 15572589
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Vaccine. 2016 May 27;34(25):2834-40
pubmed: 27108193
Oncotarget. 2016 Jul 19;7(29):46653-46661
pubmed: 27270307
Immunol Rev. 2005 Jun;205:158-69
pubmed: 15882352
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
J Clin Oncol. 2009 Jun 10;27(17):2758-65
pubmed: 19403886
J Leukoc Biol. 2013 Apr;93(4):633-7
pubmed: 23341539
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20012-7
pubmed: 22123971
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Cancer Immunol Immunother. 2016 Jan;65(1):37-45
pubmed: 26589409
Biol Chem. 2008 May;389(5):561-8
pubmed: 18953723
Blood. 2011 Aug 4;118(5):1294-304
pubmed: 21562046
Clin Cancer Res. 2018 Nov 1;24(21):5347-5356
pubmed: 29898988
PLoS Pathog. 2015 Jul 23;11(7):e1005027
pubmed: 26204259
Eur J Cancer. 2013 Jul;49(11):2522-30
pubmed: 23571147
HNO. 2018 Mar;66(3):212-218
pubmed: 29460015
Aging Cell. 2012 Jun;11(3):509-19
pubmed: 22372596
Immunol Rev. 2005 Jun;205:5-6
pubmed: 15882340
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15053-8
pubmed: 14657384
Head Neck. 2015 Mar;37(3):449-59
pubmed: 24803283
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
J Immunol. 2008 Aug 1;181(3):1835-48
pubmed: 18641321
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Nat Immunol. 2018 Jan;19(1):10-19
pubmed: 29242543
Ann N Y Acad Sci. 2006 May;1067:152-7
pubmed: 16803980
Curr Opin Immunol. 2012 Aug;24(4):482-7
pubmed: 22560294
Eur J Cancer. 2017 Sep;82:155-166
pubmed: 28689093
Exp Gerontol. 2003 Sep;38(9):981-7
pubmed: 12954485
Oncoimmunology. 2019 Feb 3;8(4):e1568810
pubmed: 30906662
J Immunol. 2010 Mar 1;184(5):2518-27
pubmed: 20100933